Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
59.89
87.8
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Shenzhen New Industries Biomedical Engineering Co Ltd
Shenzhen New Industries Biomedical Engineering Co Ltd
Cash from Operating Activities
Shenzhen New Industries Biomedical Engineering Co Ltd
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
Cash from Operating Activities
¥1.4B
|
CAGR 3-Years
13%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
Shandong Weigao Group Medical Polymer Co Ltd
HKEX:1066
|
Cash from Operating Activities
¥2.7B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Eyebright Medical Technology Beijing Co Ltd
SSE:688050
|
Cash from Operating Activities
¥212.6m
|
CAGR 3-Years
20%
|
CAGR 5-Years
46%
|
CAGR 10-Years
N/A
|
|
|
Autobio Diagnostics Co Ltd
SSE:603658
|
Cash from Operating Activities
¥1.4B
|
CAGR 3-Years
2%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Winner Medical Co Ltd
SZSE:300888
|
Cash from Operating Activities
¥1.1B
|
CAGR 3-Years
-39%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
|
Intco Medical Technology Co Ltd
SZSE:300677
|
Cash from Operating Activities
¥775.5m
|
CAGR 3-Years
-60%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
Shenzhen New Industries Biomedical Engineering Co Ltd
Glance View
Shenzhen New Industries Biomedical Engineering Co. Ltd. (SNIB) stands at the forefront of innovation in the biomedical sector, specializing in the development and manufacturing of cutting-edge medical devices and diagnostic solutions. Founded in a thriving economic hub, Shenzhen, the company harnesses state-of-the-art technology and research expertise to deliver products that enhance healthcare outcomes. With a robust portfolio that spans various therapeutic areas, including critical care, cardiology, and infectious diseases, SNIB is not only committed to advancing healthcare but also to addressing pressing global health challenges. Their dedication to research and development, coupled with strategic partnerships with leading research institutions, positions them as a significant player in the rapidly expanding biomedical market. For investors, SNIB represents a compelling opportunity driven by a combination of strong growth potential and strategic ambition. The company has consistently demonstrated impressive revenue growth, complemented by a commitment to innovation, which has resulted in a growing pipeline of products that meet both current and emerging healthcare needs. With the rising demand for advanced medical solutions globally, SNIB is poised to leverage its technological strengths and market position to capture an increasing share of this burgeoning industry. Additionally, the company's proactive approach to regulatory compliance and quality assurance underscores its commitment to delivering safe and effective products, further enhancing investor confidence in its long-term viability and success.
See Also
What is Shenzhen New Industries Biomedical Engineering Co Ltd's Cash from Operating Activities?
Cash from Operating Activities
1.4B
CNY
Based on the financial report for Dec 31, 2023, Shenzhen New Industries Biomedical Engineering Co Ltd's Cash from Operating Activities amounts to 1.4B CNY.
What is Shenzhen New Industries Biomedical Engineering Co Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
15%
Over the last year, the Cash from Operating Activities growth was 47%. The average annual Cash from Operating Activities growth rates for Shenzhen New Industries Biomedical Engineering Co Ltd have been 13% over the past three years , 15% over the past five years .
You don't have any saved screeners yet
